Albany, NY -- (SBWIRE) -- 08/03/2015 -- The incidence of liver cancer and kidney cancer in China grows gradually. According to the Guidelines for Kidney Cancer Diagnosis and Treatment in China (the 2013 version), kidney cancer accounts for 2%-3% of adult malignant tumors in China and reports an obvious rise in incidence in recent years in China. Kidney cancer has surpassed bladder cancer to become the first in death related with urological tumors with its incidence growing at an average rate of 6.5% during the past two decades.

Browse Complete Report with Toc: http://www.marketresearchreports.biz/analysis/302630

According to the World Cancer Report 2014, China ranked first in the new cases of liver cancer and its death toll. Currently, liver cancer, with 0.257 in 1 million suffering from it, has become the third malignant tumor after stomach cancer and lung cancer in terms of mortality. As a novel small molecular multi-targeted inhibitor of tyrosine kinase, sorafenib is approved by FDA to treat unresectable advanced renal cell carcinoma and unresectable or metastasized primary hepatocellular carcinoma. Co-developed by Bayer and Onyx Pharmaceuticals, sorafenib got imported drug license in 2006 and was approved by China Food and Drug Administration to enter the market for the treatment of liver cancer in 2008.

According to CRI's survey on 20 sample hospitals in key regions in China, sales value of sorafenib was CNY 147 million in 2013 and CNY 165 million in 2014, increasing 12.24% year on year.

Download The sample Copy Of This Report: http://www.marketresearchreports.biz/sample/sample/302630

With the degradation of environmental pollution and changes in lifestyle, the incidence of liver cancer keeps rising. Hence the vast demand for sorafenib in China. Currently, sorafenib in the Chinese market all come from Bayer AG i.e. Bayer enjoys a market share of 100%.

Readers can get at least the following information from this report:
market size of sorafenib in China
major manufacturers of sorafenib in Chinese market
retail price of sorafenib in China
market outlook of sorafenib in China
The author suggests the following groups of people purchase this report:
manufacturers of anti-tumor drugs
investors/ research institutions interested in Chinese medicine market
any interest in the medicine market, please contact CRI for customized survey service

About MarketResearchReports.biz
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

To View The Top Related News: http://www.marketresearchreports.biz/articles

Contact
Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/